Virtuvax to attend DCVMN in Kunming

Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F vaccine technology. If you are interested, I would be most interested to meet you at the developing countries vaccine manufacturers network (DCVMN) annual meeting in Kunming, China, from October 29 - 31 2018.

Tags: vaccine development, disruptive technology, biosimilar, monoclonal antibody, vaccine technology, DCVMN, Kunming, vaccine consultancy, RSV, pre-fusion RSV-F, RSV vaccine, pneumococcal vaccine

Virtuvax to attend DCVMN in Kunming

Featured Posts

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Recent Posts

Mucosis Announces Re-issue of Major Patent by US Patent Office USPTO

SynGEM publication paper of the month on ReSViNET

First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I

New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV c

Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV)

Virtuvax to attend DCVMN in Kunming

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?

Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”

Meet Virtuvax @ BioWin Day 2016

Archive

Search By Tags

Follow Us